GCLabs

Search for Test Items

Non-hereditary solid tumor gene panel test (+RNA)

GC Labs code	F147	Test Field	Human genetics
Compulsory forms	Oncology requisition and consent form, GC Genome Informed consent for genetic testing

GC Labs code

F147

Test Field

Human genetics

Compulsory forms

Oncology requisition and consent form, GC Genome Informed consent for genetic testing

Information

Test method	NGS (Next generation sequencing)
Specimen (mL)	Unstained slide 16 section & H&E slide Needle biopsy 20 section & H&E slide
Specimen storage	Ambient
Specimen stability	-
Test schedule	Mon-Fri
Analytical time (day)	14

Test method

NGS (Next generation sequencing)

Specimen (mL)

Unstained slide 16 section & H&E slide
Needle biopsy 20 section & H&E slide

Specimen storage

Ambient

Specimen stability

Test schedule

Mon-Fri

Analytical time (day)

Reference range/Unit	[Unstain slide] See comments in the report [aspirate] See comments in the report
Clinical Significance	It is a test for the treatment decision of malignant solid cancers such as gastric cancer, lung cancer, colon cancer, breast cancer, ovarian cancer, melanoma, gastrointestinal stromal tumor, cerebral spinal cord malignancies, childhood neuroblastoma, and unknown primary cancer. DNA and RNA are extracted from tumor tissues and FFPE specimens, and mutation information of about 500 genes is analyzed. Also, SNV, small indel, copy number variant, and fusion are detected, and TMB score and MSI status are additionally reported. However, when reporting the results, only the mutations corresponding to tier 1 and tier 2 are reported, and tier 3 and tier 4 are not reported.
Remark	[Specimen Handling] Unstained slide: Diameter ≥ 1.0 cm, thickness 10 μm [Precautions & Cautions] ① Mark the "lesion area" on the H&E slide ② Submission is acceptable only when tumor cellularity (number of malignant nuclei / number of all nuclei) ≥ 30%

Reference range/Unit

 [Unstain slide]
See comments in the report

 [aspirate]
See comments in the report

Clinical Significance

It is a test for the treatment decision of malignant solid cancers such as gastric cancer, lung cancer, colon cancer, breast cancer, ovarian cancer, melanoma, gastrointestinal stromal tumor, cerebral spinal cord malignancies, childhood neuroblastoma, and unknown primary cancer. DNA and RNA are extracted from tumor tissues and FFPE specimens, and mutation information of about 500 genes is analyzed. Also, SNV, small indel, copy number variant, and fusion are detected, and TMB score and MSI status are additionally reported. However, when reporting the results, only the mutations corresponding to tier 1 and tier 2 are reported, and tier 3 and tier 4 are not reported.

Remark

[Specimen Handling]
Unstained slide: Diameter ≥ 1.0 cm, thickness 10 μm

[Precautions & Cautions]
① Mark the "lesion area" on the H&E slide
② Submission is acceptable only when tumor cellularity (number of malignant nuclei / number of all nuclei) ≥ 30%